Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Show Differences in Autoantibody Signatures Based on Disease Activity

Biomolecules. 2023 Sep 15;13(9):1392. doi: 10.3390/biom13091392.

Abstract

Systemic juvenile idiopathic arthritis (SJIA) is a severe rheumatic disease in children. It is a subgroup of juvenile idiopathic arthritis (JIA; MIM #604302), which is the most common rheumatic disease in children. The diagnosis of SJIA often comes with a significant delay, and the classification between autoinflammatory and autoimmune disease is still discussed. In this study, we analyzed the immunological responses of patients with SJIA, using human proteome arrays presenting immobilized recombinantly expressed human proteins, to analyze the involvement of autoantibodies in SJIA. Results from group comparisons show several differentially reactive antigens involved in inflammatory processes. Intriguingly, many of the identified antigens had a high reactivity against proteins involved in the NF-κB pathway, and it is also notable that many of the detected DIRAGs are described as dysregulated in rheumatoid arthritis. Our data highlight novel proteins and pathways potentially dysregulated in SJIA and offer a unique approach to unraveling the underlying disease pathogenesis in this chronic arthropathy.

Keywords: autoantibodies; protein microarray; systemic autoinflammatory disease; systemic juvenile idiopathic arthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arthritis, Juvenile*
  • Arthritis, Rheumatoid*
  • Autoantibodies
  • Child
  • Humans
  • NF-kappa B
  • Rheumatic Diseases*

Substances

  • Autoantibodies
  • NF-kappa B

Grants and funding

This research was funded by an E-Rare-3 program (INSAID—9003037603); FWF Austrian Science Fund (I 2742 International Projects, I 5899 International Projects); and the European Union’s ERAPerMED programme (grant agreement No 2021-262).